Jason D. Mitchell

Array ( [id] => 17241999 [patent_doc_number] => 20210361742 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-25 [patent_title] => PEPTIDE THERAPEUTICS FOR THE TREATMENT OF CANCER AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/272160 [patent_app_country] => US [patent_app_date] => 2019-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16214 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -48 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17272160 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17292250 [patent_doc_number] => 20210388089 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-16 [patent_title] => ANTIGEN BINDING AGENTS THAT BIND CD277 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/267398 [patent_app_country] => US [patent_app_date] => 2019-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36467 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -66 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17267398 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17548178 [patent_doc_number] => 20220119519 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-21 [patent_title] => SIRP1A TARGETED CHIMERIC PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/266250 [patent_app_country] => US [patent_app_date] => 2019-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 83428 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -72 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17266250 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19060168 [patent_doc_number] => 11939377 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-26 [patent_title] => Affinity matured CD22-specific monoclonal antibody and uses thereof [patent_app_type] => utility [patent_app_number] => 17/259334 [patent_app_country] => US [patent_app_date] => 2019-07-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 46 [patent_figures_cnt] => 58 [patent_no_of_words] => 22567 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17259334 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17792135 [patent_doc_number] => 20220251226 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-11 [patent_title] => ANTI-BCMA SINGLE DOMAIN ANTIBODIES AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 17/270788 [patent_app_country] => US [patent_app_date] => 2019-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7145 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17270788 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17067295 [patent_doc_number] => 20210269510 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-02 [patent_title] => ANTIBODIES HAVING SPECIFICITY FOR THE ORF2I PROTEIN OF HEPATITIS E VIRUS AND USES THEREOF FOR DIAGNOSTIC PURPOSES [patent_app_type] => utility [patent_app_number] => 17/257966 [patent_app_country] => US [patent_app_date] => 2019-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6938 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17257966 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17170379 [patent_doc_number] => 20210324049 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-21 [patent_title] => ANTIBODIES HAVING SPECIFICITY FOR THE ORF2I PROTEIN OF HEPATITIS E VIRUS AND USES THEREOF FOR DIAGNOSTIC PURPOSES [patent_app_type] => utility [patent_app_number] => 17/258891 [patent_app_country] => US [patent_app_date] => 2019-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6641 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17258891 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20548790 [patent_doc_number] => 12559570 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-02-24 [patent_title] => Anti-PAD2 antibody [patent_app_type] => utility [patent_app_number] => 16/972832 [patent_app_country] => US [patent_app_date] => 2019-06-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 3 [patent_no_of_words] => 5873 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16972832 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17067310 [patent_doc_number] => 20210269525 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-02 [patent_title] => ANTI-CD3e ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/256455 [patent_app_country] => US [patent_app_date] => 2019-06-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25699 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17256455 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18995936 [patent_doc_number] => 11912763 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-02-27 [patent_title] => Antibody targeting CLDN18.2, bispecific antibody, ADC, and CAR, and applications thereof [patent_app_type] => utility [patent_app_number] => 17/252259 [patent_app_country] => US [patent_app_date] => 2019-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 52981 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 128 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17252259 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16854968 [patent_doc_number] => 20210155713 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-27 [patent_title] => ENTPD2 ANTIBODIES, COMBINATION THERAPIES, AND METHODS OF USING THE ANTIBODIES AND COMBINATION THERAPIES [patent_app_type] => utility [patent_app_number] => 17/058870 [patent_app_country] => US [patent_app_date] => 2019-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 93342 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -77 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17058870 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18948164 [patent_doc_number] => 11891445 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-02-06 [patent_title] => Anti-B7-H3 antibody and use thereof [patent_app_type] => utility [patent_app_number] => 17/057643 [patent_app_country] => US [patent_app_date] => 2019-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 25990 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 254 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17057643 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17156359 [patent_doc_number] => 20210317410 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-14 [patent_title] => METHODS OF MAKING NATURAL KILLER CELLS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/058430 [patent_app_country] => US [patent_app_date] => 2019-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16025 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17058430 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16946761 [patent_doc_number] => 20210205452 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-08 [patent_title] => Composition of Concentrated Human Immunoglobulins [patent_app_type] => utility [patent_app_number] => 17/056626 [patent_app_country] => US [patent_app_date] => 2019-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5124 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17056626 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16915888 [patent_doc_number] => 20210188980 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-24 [patent_title] => HIGH AFFINITY ANTIBODIES TO PD-1 AND LAG-3 AND BISPECIFIC BINDING PROTEINS MADE THEREFROM [patent_app_type] => utility [patent_app_number] => 17/051834 [patent_app_country] => US [patent_app_date] => 2019-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36164 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17051834 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16776585 [patent_doc_number] => 20210113662 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-22 [patent_title] => COMPOSITIONS AND METHODS FOR THE TREATMENT OF ISCHEMIA AND CARDIOMYOPATHY [patent_app_type] => utility [patent_app_number] => 17/048535 [patent_app_country] => US [patent_app_date] => 2019-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20575 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17048535 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17036756 [patent_doc_number] => 20210253714 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-19 [patent_title] => STABLE ANTIBODY FORMULATION [patent_app_type] => utility [patent_app_number] => 17/045336 [patent_app_country] => US [patent_app_date] => 2019-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3437 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17045336 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16854945 [patent_doc_number] => 20210155690 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-27 [patent_title] => COMPOSITIONS AND METHODS FOR THE IMMUNE CHECKPOINT BLOCKADE OF TIM4 [patent_app_type] => utility [patent_app_number] => 17/046352 [patent_app_country] => US [patent_app_date] => 2019-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15988 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -42 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17046352 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16710330 [patent_doc_number] => 20210077477 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-18 [patent_title] => MICROGLIA MODULATORS FOR USE IN TREATMENT OF DEPRESSION [patent_app_type] => utility [patent_app_number] => 16/963732 [patent_app_country] => US [patent_app_date] => 2019-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20488 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16963732 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16839532 [patent_doc_number] => 20210147544 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-20 [patent_title] => METHODS AND COMPOSITIONS FOR TARGETED DELIVERY OF ACTIVE AGENTS AND IMMUNOMODULATORY AGENTS TO LYMPH NODES [patent_app_type] => utility [patent_app_number] => 16/981758 [patent_app_country] => US [patent_app_date] => 2019-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29373 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16981758 [rel_patent_id] =>[rel_patent_doc_number] =>)